Squarepoint’s Orchestra BioMed OBIO Stock Holding History

Squarepoint’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-44,343	Closed	-$184K	–	4748
2025 Q4	$184K	Buy	+44,343	New	+$179K	﹤0.01%	3897
2025 Q3	–	Sell	-28,221	Closed	-$75.6K	–	4793
2025 Q2	$75.6K	Buy	+28,221	New	+$82.4K	﹤0.01%	4226

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Squarepoint's OBIO Position: Q1 2026 in Review

Squarepoint sold out of Orchestra BioMed (OBIO) in Q1 2026, closing a stake of 44,343 shares — an estimated $184K sold.

Squarepoint first reported a position in OBIO in Q2 2025 and held it in 2 quarters. The position peaked at $184K in Q4 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

Squarepoint reported no remaining Orchestra BioMed position as of Q1 2026 after selling out during the quarter.
Squarepoint sold 44,343 Orchestra BioMed shares in Q1 2026, an estimated $184K.
Squarepoint first reported a position in Orchestra BioMed in Q2 2025 and held it in 2 quarters.
Squarepoint's Orchestra BioMed position peaked at $184K in Q4 2025.
65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.